Boule Diagnostics (publ) Year-end report January–December 2021
Finishing the year with record quarter
Quarter October-December 2021
- Net sales amounted to SEK 140.3 (92.7) million, an increase of 51.4 percent. After adjustment for currency effects, the increase is 50.3 percent.
- The number of instruments sold amounted to 1,326 (834), an increase of 59 percent.
- Cash flow from operating activities amounted to SEK 11.8 (25.3) million.
- Operating profit was SEK 13.8 (-41.6) million, corresponding to an operating margin of 9.9 (-44.9) percent. Operating profit for 2020 included a write-off of intangible assets (-40.0 million).
- Profit after tax amounted to SEK 17.3 (-32.6) million.
- Earnings per share before dilution amounted to SEK 0.89 (-1.68) and after dilution amounted to SEK 0.87 (-1.63).
Full year January–December 2021
- Net sales amounted to SEK 463.3 (400.5) million, an increase of 15.7 percent. After adjustment for currency effects, the increase is 20.8 percent.
- The number of instruments sold amounted to 4,227 (3,047), an increase of 39 percent.
- Cash flow from operating activities amounted to SEK 43.2 (75.2) million.
- Operating profit/loss was SEK 36.0 (-5.9) million which corresponds to an operating margin of 7.8 (-1.5) percent.
- Net profit/loss amounted to SEK 23.3 (-48.0) million.
- Earnings per share before dilution amounted to SEK 1.20 (-2.47) and after dilution amounted to SEK 1.17 (-2.40).
- The Board of Directors proposes a dividend of SEK 0.55 per share for 2021 (0.55).
CEO Jesper Söderqvist
Record sales for the quarter and good profit growth
Net sales for Q4 2021 were SEK 140 million, corresponding to growth of 51 percent compared with the same period the previous year. This is also SEK 9 million better than the previous record quarter, Q3 2019. Although all markets are still affected by the pandemic, Boule sees a positive trend in both sales and order intake. Sales of consumables increased by 47 percent compared with the previous year and by 23 percent compared with Q3 2021, and are now above the pre-pandemic level. This was also a record quarter in terms of the number of instruments delivered and OEM sales, with revenue increase of 45 percent and 110 percent respectively compared with the previous year. This growth is due to a recovery after the pandemic, continued growth in our OEM business and the fact that our market efforts in the Middle East and Africa are starting to generate results.
The shortage of electronic and other components continued to present significant challenges for our production. Thanks to hard work, we have managed to deliver, but this has also led to increased costs, affecting both the gross margin and other operating expenses. The gross margin for the quarter was 41.2 percent, and was also affected by a product mix with a higher proportion of instruments to India and increased OEM sales.
Operating profit was SEK 13.8 million, corresponding to an operating margin of 9.9 percent. The result has been adversely affected by additional costs for components, overtime, redesigns and higher transport costs corresponding to approximately SEK 6 million.
Operating cash flow was SEK 12 million. During the quarter, SEK 15 million was invested in Boule’s new product platform.
Fantastic result from the entire organization and our partners during 2021
Being able to deliver our best-ever quarterly sales during an ongoing pandemic is possible thanks to the hard work of all my colleagues and solid cooperation with all our partners. I want to thank everyone for their fantastic efforts during a challenging year. We have seen gradual improvements every quarter in 2021. However, the real increase did not come until the fourth quarter, even though the challenges in the supply chain remained. For the full year, sales increased by 16% to SEK 463 million and operating profit was SEK 36 million, corresponding to an operating margin of 7,8 percent. I am very proud of the way we handled all the challenges during the last year.
Highly positive development of the OEM business
Boule is one of the few manufacturers that develops and manufactures instruments, reagents, blood tests and calibrators. This makes us a sought-after partner for other manufacturers too, which is a competence that we are working strategically to leverage. The OEM business, in which we sell consumables to other manufacturers, has grown by 43 percent for the full year 2021, largely due to the contract signed in 2020. Our OEM customers are announcing increasing sales forecasts for 2022.
A milestone in our transition to the new IVDR European regulatory framework
The new regulatory framework in Europe, the IVDR, will be introduced in May 2022. The introduction of the IVDR passed an important milestone in November, when a second and final audit of Boule’s quality system was completed with zero non-conformances. It was extremely encouraging to receive recognition of the work the organization has put in over a long period to adapt the quality system.
The proposed deferral of the phased introduction of the IVDR for certain risk classes of products has now been adopted by the EU. Boule will update the product documentation for certain products with a lower risk classification, referred to as self-certification, during 2022. For older products with a higher risk classification, the IVDR transition deadline is May 2027.
Good momentum with new product platform and innovation
Our new hematology platform is approaching the final design for the first instrument, an advanced 5-part system for the global human market. Here too, the availability of materials and components to build the instruments for clinical validation is a challenge. The timeline for the start of the clinical validation of instruments and consumables has been pushed forward slightly, and with it also the launch, which will now be in early 2023.
The new platform also includes a cloud-based infrastructure and services based on it. This is on track for a planned launch in late 2022, when some of the existing active instruments will be able to take advantage of the new service offering.
The portfolio will be continuously upgraded based on the new platform, with new product and service offerings over the next 2-5 years.
Annette Colin new CFO
In April, Annette Colin takes over as CFO from Christina Rubenhag, who is moving on to become CFO of Addlife. I would like to thank Christina for her excellent cooperation and for her contribution to Boule’s development and I wish her all the best for the future. At the same time, I am delighted to welcome Annette to Boule. Annette has broad experience in leading finance organizations in global companies and in strategic change management and will be a key person in Boule’s further development.
We start 2022 with a well-filled order book
It is difficult to predict the market development for 2022. However, most signs point to a continued recovery, even if challenges with disturbances with components and logistics persist. Boule has a large number of active instruments in developing countries that have low vaccination rates. In the slightly longer term, we expect test volumes to return to more normal levels in these countries too, which will contribute to increased sales of consumables and improved profitability.
As a company, we continue to adapt to ever-changing conditions. In early 2022, we are increasing our prices to our distributors in order to reduce the margin impact of higher prices of materials and additional costs in the logistics chain. In 2021, we have worked purposefully to strengthen Boule’s market presence and manage the impact of the pandemic in parallel with our strategic development projects. Our commercial team and distributors have been successful in generating and securing business over the last year, significantly increasing the order intake. Some of the order backlog from the fourth quarter will be carried into the new year, which we start with a much larger than normal order book. We see profitability continuing its gradual improvement, with increasing volumes and a world that is returning to normality. We leave 2021 a stronger company and look forward to what appears to be a promising 2022.
THE YEAR-END REPORT IS FOUND BELOW AS A PDF OR AS AN ONLINE-VERSION AT BOULE.COM
Presentation of the year-end report
At 09.00 CEO Jesper Söderqvist and CFO Christina Rubenhag will present and comment on the year-end report.
After the presentation there will be time for audience questions. The presentation will be held in English.
Please follow this link to participate.
For more information, please contact:
Jesper Söderqvist, CEO and Group President, Boule Diagnostics AB, phone +46 (0)70-689 05 90
Christina Rubenhag, CFO, Boule Diagnostics AB, phone +46 (0)70-546 72 22
About Boule Diagnostics AB (publ)
Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA, Mexico and Russia. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. http://www.boule.com
This information is information that Boule Diagnostics AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation.
The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CET on February 3, 2022.
